Orforglipron vs Retatrutide

Orforglipron wins for oral convenience, day-to-day flexibility, and a side-effect profile that's generally easier to manage in mild or moderate cut protocols. It's ideal as a maintenance or long-term appetite-suppression agent where frequent injections are a non-starter.

Retatrutide wins for raw body-fat reduction—nothing on the scene matches its efficacy. The triple agonist action (GLP-1, GIP, glucagon) crushes visceral and hepatic fat, increases energy expenditure, and delivers deeper and faster cuts. The trade-off: a peptide-only format (weekly injection), higher rates of GI side effects, and less forgiveness for slip-ups in titration or nutrition.

Pick Orforglipron if:

• Oral administration is non-negotiable—no desire for injections or cold-chain logistics
• Appetite suppression is needed but not at maximum intensity; maintenance-phase or mild deficit protocols
• The goal is to stack with other orals (GH secretagogues, DHT derivatives) for a streamlined daily routine
• There's a premium on flexibility—missed doses are well tolerated due to long half-life
• Lower risk of severe GI events or discontinuation is a priority

Pick Retatrutide if:

• The priority is maximum fat loss, including rapid reductions in visceral and liver fat
• Plateaued on semaglutide or tirzepatide and need the next step up in body-fat reduction
• Weekly injection protocol is acceptable and logistics are not an obstacle
• Aggressive cut-phase protocols, deep stage-prep, or post-blast fat cleanup are in play
• Willing to manage a more aggressive titration and side-effect profile to reach peak efficacy